Baseline Characteristic | Extrafine-particle ICSa (n = 1399) | Fine-particle ICSb (n = 1399) | p-value | |
---|---|---|---|---|
Sex, male, n (%)c | 471 (34) | 471 (34) | N/A | |
Age, median (IQR)c | 43 (32–53) | 43 (32–52) | 0.091 | |
Year of initiation date, median (IQR)c | 2008 (2006–2009) | 2008 (2006–2009) | N/A | |
ICS dose prescribed on initiation date, n (%) | ||||
<200μg/d, n (%) | 866 (62) | 218 (16) | <0.001 | |
201–400μg/d, n (%) | 477 (34) | 301 (22) | ||
401–800μg/d, n (%) | 56 (4) | 677 (48) | ||
801μg/d, n (%) | 0 (0) | 203 (15) | ||
ICS dose on initiation date, median (IQR) | 160 (160–320) | 500 (250–500) | <0.001 | |
Average ICS daily dose (μg/d, categorized EF-HFA-BDP/ciclesonide equivalent dosed) | ||||
0–200μg/d, n (%) | 866 (62) | 218 (16) | <0.001 | |
201–400μg/d, n (%) | 477 (34) | 301 (22) | ||
401–800μg/d, n (%) | 56 (4) | 677 (48) | ||
801μg/d+, n (%) | 0 (0) | 203 (15) | ||
Recorded comorbidity, n (%) | ||||
Rhinitis diagnosis, n (%) | 623 (45) | 536 (38) | <0.001 | |
GERD diagnosis, n (%) | 513 (37) | 437 (31) | 0.001 | |
Paracetamol script, n (%) | 28 (2) | 47 (3) | 0.020 | |
NSAID script, n (%) | 219 (16) | 215 (15) | 0.834 | |
Topical corticosteroid treatment, n (%) | 433 (31) | 374 (27) | 0.014 | |
Oral candidiasis diagnosis, n (%) | 14 (1) | 11 (1) | 0.533 | |
Rhinitis diagnosis, n (%) | Ciclesonide | 18 (1) | N/A | N/A |
EF-HFA-BDP | 21 (1) | |||
GERD diagnosis, n (%) | Ciclesonide | 0 (0) | N/A | N/A |
EF-HFA-BDP | 1 (1) | |||
Topical corticosteroid treatment, n (%) | Ciclesonide | 207 (15) | N/A | N/A |
EF-HFA-BDP | 226 (16) | |||
Respiratory Medications | ||||
Acute oral corticosteroid prescriptions, <1, n (%) | 101 (7) | 120 (9) | 0.001 | |
Acute oral corticosteroid prescriptions, <1, n (%) | Ciclesonide | 47 (3) | N/A | N/A |
EF-HFA-BDP | 54 (4) | |||
SABA daily dose, n (%)c | ||||
0μg/d, n (%) | 953 (68) | 953 (68) | N/A | |
200μg/d, n (%) | 57 (4) | 57 (4) | ||
201μg/d, n (%) | 40 (3) | 40 (3) | ||
SABA prescriptions, n (%) | ||||
0, n (%)c | 953 (68) | 953 (68) | 0.251 | |
1, n (%) | 281 (20) | 267 (19) | ||
2+, n (%) | 165 (12) | 179 (13) | ||
Prior therapy | ||||
LABA, n (%)c | 21 (2) | 21 (2) | N/A | |
LTRA, n (%)c | 1 (0) | 1 (0) | N/A | |
Asthma control | ||||
Risk-domain asthma control, n (%)c | 1275 (91) | 1275 (91) | N/A | |
Overall asthma control, n (%)c | 1241 (89) | 1241 (89) | N/A | |
Severe exacerbations, n (%)c | ||||
0 | 1275 (91) | 1275 (91) | N/A | |
1 | 109 (8) | 109 (8) | ||
2+ | 15 (1) | 15 (1) | ||
Asthma-related hospital admissions, n (%) | 23 (2) | 4 (0) | 0.001 | |
Asthma-related hospital admissions, n (%) | Ciclesonide | 11 (1) | N/A | N/A |
EF-HFA-BDP | 12 (1) |